pharmaasiaJuly 13, 2017
Tag: Yungjin Pharm , NeuroVive , china
NeuroVive Pharmaceutical AB and Yungjin Pharm Corporation Ltd (South Korea Stock Market, KRX 003520) announced that the clinical phase I study of KL1333 has started in Korea and that the first healthy volunteer has been enrolled.
The study is a double-blind, placebo-controlled, single-dose, dose-escalation phase I clinical study to investigate the pharmacokinetics and safety/tolerability of KL1333 in healthy subjects. The study is planned to encompass a total of 60 healthy volunteers and will be fully performed by Yungjin Pharm. KL1333 is in development for the treatment of genetic mitochondrial diseases, such as MELAS and Kearns-Sayre syndrome, for which there are no current medicines.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: